Toronto Stock Exchange Symbol: MS
EDMONTON, May 13 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS),
a leading developer in the treatment of multiple sclerosis (MS), today
announced that Dr. Mark Krantz, Vice President Scientific Affairs, BioMS
Medical, will present at the TIDES(R) - Oligonucleotide and Peptide
Technology and Product Development Conference in Las Vegas.
WHEN: Tuesday May 20th at 10:45 am (PDT)
WHERE: Red Rock Casino, Resort and Spa, Las Vegas
TITLE: "Late-Stage Clinical Development of Synthetic Peptide MBP8298
for the Treatment of Multiple Sclerosis"
About TIDES(R) Conference
------------------------- TIDES(R) is the only forum that covers manufacturing, formulation, delivery, process and analytical development and overall market trends for peptide- and oligonucleotide-based therapeutics and diagnostics. For more information visit: http://www.ibclifesciences.com/tides/8490.xml
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and
commercialization of novel therapeutic technologies. BioMS Medical's lead
technology, MBP8298, is for the treatment of multiple sclerosis and is
being evaluated in two pivotal phase III clinical trials for secondary
progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in
the United States. It additionally is being evaluated for relapsing
remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In
December 2007, BioMS entered into a licensing and development agreement
granting Eli Lilly and Company exclusive worldwide rights to MBP8298 in
exchange for an $87 million upfront payment, milestone payments and
escalating royalties on sales. For further information please visit our
website at '/>"/>
|SOURCE BioMS Medical Corp.|
Copyright©2008 PR Newswire.
All rights reserved